title: A phase III open randomized study of Zoladex 3.6 mg depot vs. DES 3 mg per day in untreated advanced prostate cancer: a West Midlands Urological Research Group Study.
authors.affiliation: West Midlands Cancer Research Campaign Clinical Trials Unit, Queen Elizabeth Hospital, Birmingham, UK.
authors.forename: L A
authors.initials: LA
authors.lastname: Emtage
authors.forename: C
authors.initials: C
authors.lastname: Trethowan
authors.forename: K
authors.initials: K
authors.lastname: Kelly
authors.forename: D
authors.initials: D
authors.lastname: Arkell
authors.forename: D M
authors.initials: DM
authors.lastname: Wallace
authors.forename: M
authors.initials: M
authors.lastname: Hughes
authors.forename: A
authors.initials: A
authors.lastname: Hay
authors.forename: R
authors.initials: R
authors.lastname: Blacklock
authors.forename: M
authors.initials: M
authors.lastname: Jones
authors.forename: A
authors.initials: A
authors.lastname: Rouse
mesh_terms: D000368:Aged; D002064:Buserelin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004054:Diethylstilbestrol / Q000008:administration & dosage / Q000627:therapeutic use*; D017273:Goserelin; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011897:Random Allocation; D006113:United Kingdom
chemical_list: D003692:Delayed-Action Preparations; D017273:Goserelin; D004054:Diethylstilbestrol; D002064:Buserelin